Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

(2021) David A. Reardon et al.   CANCER

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

(2021) Matthias Gromeier et al.   Nature Communications

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development

(2021) Bernarda Majc et al.   Cells

Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.

(2020) Michael Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).

(2020) Shiao-Pei S. Weathers et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms and therapeutic implications of hypermutation in gliomas

(2020) Mehdi Touat et al.   NATURE

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

(2020) Bas Weenink et al.   Cancers

Management of glioblastoma: State of the art and future directions

(2020) Aaron C. Tan et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?

(2020) Mustafa Khasraw et al.   CLINICAL CANCER RESEARCH

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis

(2020) Chengcheng Hao et al.   Frontiers in Oncology

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Management of brain metastases according to molecular subtypes

(2020) Riccardo Soffietti et al.   Nature Reviews Neurology

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

(2020) Thomas Daubon et al.   Frontiers in Immunology

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

(2020) Gil Awada et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study

(2020) Giuseppe Lombardi et al.   Cancers

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2020) Lakshmi Nayak et al.   CLINICAL CANCER RESEARCH

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

(2020) J. Bryan Iorgulescu et al.   CLINICAL CANCER RESEARCH

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

(2019) Kurt A. Schalper et al.   NATURE MEDICINE

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

(2019) William Tomaszewski et al.   CLINICAL CANCER RESEARCH

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).

(2019) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study.

(2019) Francois Henri Jacques et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of immunotherapy resistance: lessons from glioblastoma

(2019) Christopher M. Jackson et al.   NATURE IMMUNOLOGY

OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial

(2019) D Pouessel et al.   NEURO-ONCOLOGY

Role of myeloid cells in the immunosuppressive microenvironment in gliomas

(2019) Chiara V. Locarno et al.   IMMUNOBIOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM)

(2019) Sylvia Kurz et al.   NEURO-ONCOLOGY

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

(2019) J de Groot et al.   NEURO-ONCOLOGY

Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model

(2018) Bailing Dai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

Advances in Radiotherapy for Glioblastoma

(2018) Justin Mann et al.   Frontiers in Neurology

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

(2018) Alice L. Hung et al.   OncoImmunology

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma

(2018) Rimas V. Lukas et al.   JOURNAL OF NEURO-ONCOLOGY

ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

(2018) David Reardon et al.   NEURO-ONCOLOGY

Targeting Immune Checkpoints in Cancer Therapy

(2017) Suzanne L. Topalian   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The role of bevacizumab in the treatment of glioblastoma

(2017) Roberto Jose Diaz et al.   JOURNAL OF NEURO-ONCOLOGY

ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)

(2017) David Reardon et al.   NEURO-ONCOLOGY

OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143

(2017) A. Omuro et al.   NEURO-ONCOLOGY

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

(2017) Antonio Omuro et al.   NEURO-ONCOLOGY

Immunotherapy approaches in the treatment of malignant brain tumors

(2016) Anastasie M. Dunn-Pirio et al.   CANCER

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal evolution of glioblastoma under therapy

(2016) Jiguang Wang et al.   NATURE GENETICS

Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

(2016) Sarah T. Garber et al.   NEURO-ONCOLOGY

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

(2016) T. M. Johanns et al.   Cancer Discovery

Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation

(2015) KERRIE L. MCDONALD et al.   Oncology Letters

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets

(2012) Hua Mao et al.   CANCER INVESTIGATION

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY